Вопросы приемлемости и безопасности при выборе комбинированных оральных контрацептивов

1. Toffol E., Heikinheimo O., Koponen P., Luoto R., Partonen T. Hormonal contraception and mental health: results of a population-based study. Hum. Reprod. 2011; 26(11): 3085-93. https://dx.doi.org/10.1093/humrep/der269.
2. Прилепская В.Н., ред. Руководство по контрацепции. 4-е изд. М.: МЕДпресс-информ; 2017.
3. Department of Economic and Social Affairs, Population Division. Trends in contraceptive use worldwide 2015. New York: United Nations; 2015. (ST/ESA/SER.A/349)
4. Сакевич В.И. От аборта к контрацепции. Демоскоп Weekly. 2016; 687-688: 1-25.
5. Прилепская В.Н., Довлетханова Э.Р., Абакарова П.Р. От аборта к сохранению репродуктивного здоровья: новое в контрацепции. Фарматека. 2013; 12: 46-9.
6. Дикке Г.Б., Ерофеева Л.В. Контрацепция в современной России: применение и информированность (популяционное исследование). Акушерство и гинекология. 2016; 2: 108-13.
7. Федеральная служба государственной статистики. Демография. Численность и состав населения. Электронный ресурс.
8. Negriff S., Dorn L.D., Hillman J.B., Huang B. The measurement of menstrual symptoms: Factor structure of the menstrual symptom questionnaire in adolescent girls. J. Health Psychol. 2009; 14(7): 899-908.
9. Герасимова Л.И., Денисов М.С., Шувалова Н.В., Сидорова Т.Н. Репродуктивное здоровье девушек студенток как медикосоциальная проблема. Современные проблемы науки и образования. 2015; 6: 295.
10. Horibe M., Hane Y., Abe J., Matsui T., Kato Y., Ueda N. et al. Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004-2015. Nurs. Open. 2018; 5(2): 131-8. https://dx.doi.org/10.1002/nop2.121
11. Serfaty D. Update on the contraceptive contraindications. J. Gynecol. Obstet. Hum. Reprod. 2019; 48(5): 297-307. https://dx.doi.org/10.1016/j.jogoh.2019.02.006
12. FDA’s Office of Women’s Health. (2017). Medicine to Help You, Depression. Available at: http://www.fda.gov/downloads/ForConsumers/ByAudience/ForWomen/FreePublications/UCM182083.pdf aAccessed 12 January 2017.
13. МакВэй Э., Джиллбоуд Дж., Хамбеэг Р. Репродуктивная медицина и планирование семьи. Практическое руководство. Пер. с англ. Прилепская В.Н., Сухих Г.Т., ред. М.: МЕДпресс-информ; 2016.
14. Контрацепция и здоровье: звенья одной цепи. Итоги встречи российских врачей и представителей Европейского общества по контрацепции и репродуктивному здоровью (Москва, 20 марта 2012 года). М.: Редакция журнала StatusPraesens; 2012.
15. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A., Garner S.E. Combined oral сontraceptive pills for treatment of acne. Cochrane Database Syst. Rev. 2009; (3): CD00442.
16. Dinger J., Minh T.D., Buttmann N., Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet. Gynecol. 2011; 117(1): 33-40.
17. Dinger J. Comparative effectiveness of combined oral contraceptives in adolescents. J. Fam. Plann. Reprod. Health Care. 2011; 37(2): 118. https://dx.doi.org/10.1136/jfprhc.2011.0092.
18. Fenton C., Wellington K., Moen M.D., Robinson D.M. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007; 67(12): 1749-65.
19. Bonassi Machado R., Gandolpho A.C., Santana N., Bocardo R.C., Palandri N., Morassutti Machado R. Contraception for women with heart disease: an update. Minerva Ginecol. 2017; 69(3): 259-68. https://dx.doi.org/10.23736/S0026-4784.17.04041-2.
20. Westhoff C., Jones K., Robilotto C., Heartwell S., Edwards Sh., Zieman M., Cushman L. Smoking and oral contraceptive continuation. Contraception. 2009; 79(5): 375-8.
21. Nelson A. New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control. Int. J. Womens Health. 2010; 2: 99-106.
22. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
23. Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil. Steril. 2017; 107(1): 43-51. https://dx.doi.org/10.1016/j.fertnstert.2016.09.027.
24. Plu-Bureau G., Sabbagh E., Hugon-Rodin J. Hormonal contraception and vascular risk: CNGOF Contraception Guidelines. Gynecol. Obstet. Fertil. Senol. 2018; 46(12): 823-33. https://dx.doi.org/10.1016/j.gofs.2018.10.007.
25. Plu-Bureau G., Maitrot-Mantelet L., Hugon-Rodin J., Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27(1): 25-34. https://dx.doi.org/10.1016/j.beem.2012.11.002.
26. Sitruk-Ware R., Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27(1): 13-24.
27. Lopez L.M., Grimes D.A., Schulz K.F. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst. Rev. 2012; (4): CD006133.
28. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152(1): 113-25.
29. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А., Иванова Е.В., Летуновская А.Б., Набиева К.Р. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акушерство и гинекология. 2012; 2: 81-5.
30. Tepper N.K., Whiteman M.K., Marchbanks P.A., James A.H., Curtis K.M. Progestin-only contraception and thromboembolism: a systematic review. Contraception 2016; 94(6): 678-700. https://dx.doi.org/10.1016/j.contraception.2016.04.014.
31. Gryglas A., Smigiel R. Migraineandstroke:What’s thelink? Whattodo? Curr. Neurol Neurosci. Rep. 2017; 17: 22. https://dx.doi.org/10.1007/s11910-017-0729-y.
32. Cappy H., Lucas C., Catteau-Jonard S., Robin G. Migraine and contraception. Gynecol. Obstet. Fertil. 2015; 43(3): 234-41. https://dx.doi.org/10.1016/j.gyobfe.2015.01.006.
33. Kurth T., Winter A.C., Eliassen A.H., Dushkes R., Mukamal K.J., Rimm E.B. et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016; 353: i2610. https://dx.doi.org/10.1136/bmj.i2610.
34. Кузнецова И.В. Выбор комбинированной оральной контрацепции для подростков и молодых женщин. Акушерство и гинекология. 2018; 1: 35-40.
35. Conway G., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Franks S., Gambineri A. et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014; 171(4): P1-29.
36. Wichianpitaya J., Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet. Gynecol. Int. 2013; 2013: 487143.
37. Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicenter trials. Clin. Drug Invest. 2009; 29(2): 73-8.
38. Machado R.B., Pompei L.M., Giribela A.G., Giribela C.G. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond.). 2011; 7(1): 19-30. https://dx.doi.org/10.2217/whe.10.84.
39. Klipping C., Marr J., Korner P. Ovulation inhibition effects of two low-dose oral contraceptive dosing regimens following intentional dosing errors. Obstet. Gynecol. 2006; 107(4): 49S.
40. Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: A global, cross-sectional, self-administrated, online survey. Clin. Drug Investig. 2010; 30(11): 749-63.
41. Rojas-Villarraga A., Torres-Gonzalez J.V., Ruiz-Sternberg Á.M. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. PLoS One. 2014; 9(8): e104303. https://dx.doi.org/10.1371/journal.pone.0104303 eCollection 2014.
42. Andreoli L., Bertsias G.K., Agmon-Levin N., Brown S., Cervera R., Costedoat-Chalumeau N. et al. EULAR recommendations for women’s health and themanagement of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis 2017; 76(3): 476-85. https://dx.doi.org/10.1136/annrheumdis-2016-209770.
43. Gensous N., Doassans-Comby L., Lazaro E., Duffau P. Lupus érythémateux systémique et contraception : revue systématique de la littérature. Rev. Med. Interne. 2017; 38(6): 358-67.
44. Champaloux S.W., Tepper N.K., Monsour M., Curtis K.M., Whiteman M.K., Marchbanks P.A., Jamieson D.J. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am. J. Obstet. Gynecol. 2017; 216(5): 489. e1-489. e7. https://dx.doi.org/10.1016/j.ajog.2016.12.019 e1-489.e7.
45. Sacco S., Merki-Feld G.S., Ægidius K.L., Bitzer J., Canonico M., Kurth T. et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J. Headache Pain. 2017; 18 (1): 108. http://dx.doi.org/10.1186/s10194-017-0815-1.
46. Klipping C., Duijkers I., Fortier M.P., Marr J., Trummer D., Elliesen J. Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J. Fam. Plann. Reprod. Health Care. 2012; 38(2): 84-93.
47. Allais G., Chiarle G., Bergandi F., Benedetto C. The use of progestogen-only pill in migraine patients. Expert Rev. Neurother. 2016; 16(1): 71-82. https://dx.doi.org/10.1586/14737175.2016.1127161.
48. Gonçalves V., Sehivic I., Quinn G. Childbearing attitudes and decisions of young breast cancer survivors: a systematic review. Hum. Reprod. Update. 2014; 20(2): 279-92. https://dx.doi.org/10.1093/humupd/dmt039.
49. Casey P.M., Faubion S.S., MacLaughlin K.L., Long M.E., Pruthi S. Caring for the breast cancer survivor’s health and well-being. World J. Clin. Oncol. 2014; 5(4): 693-704. https://dx.doi.org/10.5306/wjco.v5.i4.693.
50. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP). Knowledge for health project. Family planning: a global handbook for providers (2011 update). Baltimore: CCP, Geneva: WHO; 2011.
51. Lynn D.D., Umari T., Dunnick C.A., Dellavalle R.P. The epidemiology of acne vulgaris in late adolescence. Adolesc. Health Med. Ther. 2016; 7: 13-25.
52. Chaiyasit N., Taneepanichskul S. A study of cycle control, side effects and client’s satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen). J. Med. Assoc. Thai. 2010; 93(5): 517-22.
53. Lidegaard Ø., Nielsen L.H., Skovlund Ch.W., Skjeldestad F.E., Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011; 343: d6423. https://dx.doi.org/10.1136/bmj.d6423.
54. Shaw K.A., Edelman A.B. Obesity and oral contraceptives: a clinician’s guide. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27(1): 55-65. https://dx.doi.org/10.1016/j.beem.2012.09.001.
55. Мгерян А.Н., Абакарова П.Р., Довлетханова Э.Р., Межевитинова Е.А. Новый режим пролонгированной гормональной контрацепции. Медицинский совет. 2017; 13: 38-42.

Поступила 18.04.2019

Принята в печать 19.04.2019